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Objective.-To examine the diagnostic accuracy of highsensitivity cardiac troponin T (hs-cTnT) assay for AMI in HD patients.
Design.-In this prospective study, we enrolled 670 consecutive stable HD patients presenting with chest pain or dyspnea on routine predialysis therapy in the nephrology department. Receiver operating characteristic (ROC) curves were used to examine the diagnostic accuracy of hscTnT levels at enrollment in HD patients presenting with chest pain or dyspnea, and the dynamic change in these levels after 3 hours.
Results.-Acute myocardial infarction was the adjudicated final diagnosis in 12% of HD patients. Among patients with a final diagnosis other than AMI, 97% had a plasma hs-cTnT concentration above the 99th percentile. At the time of enrollment, the area under the ROC curve of hs-cTnT levels for diagnosis of AMI was 0.68 (95% confidence interval [CI] , 0.62-0.74; P , .001) with a cutoff value of 107.7 ng/L; the relative change after 3 hours was 0.90 (95% CI, 0.82-0.96, P , .001) with a cutoff value of 24%, and the absolute change was 0.88 (95% CI, 0.82-0.94, P , .001) with a cutoff value of 32.6 ng/L. The prognostic value for 40-day mortality varied with the magnitude of elevation in hs-cTnT levels.
Conclusions.-Tracking the dynamic change in hs-cTnT levels during the short term significantly increased this measure's diagnostic accuracy for AMI in HD patients. T he most common cause of death among hemodialysis (HD) patients is cardiac death-predominantly acute myocardial infarction (AMI), which accounts for approximately 50% of all deaths. 1 Rapid and accurate diagnosis of AMI is an urgent clinical need, as delays increase the risk of mortality. 2, 3 Delayed exclusion of this diagnosis prolongs hospital length of stay, increases patients' anxiety, and carries enormous costs for the health care system. 4 Cardiac troponins have become the gold standard for diagnosing AMI in the general population. 5, 6 However, patients with end-stage renal disease (ESRD) have a high incidence of baseline elevation of troponins, [7] [8] [9] making the diagnosis of AMI in patients with ESRD more difficult. According to the clinical practice guidelines of the National Academy of Clinical Biochemistry, measurement of cardiac troponin T (cTnT) concentration is warranted for evaluating AMI in the population with renal failure for those who present with symptoms, electrocardiographic findings, or other clinical evidence suggestive of myocardial ischemia. 10 The newest generation of cTnT assays has a 10-to 100-fold reduced limit of detection, below the 99th percentile of a normal reference population, and these assays are being adopted by a growing number of medical institutions. These assays improve early diagnosis of AMI in the general patient population presenting with acute chest pain. [11] [12] [13] [14] However, their diagnostic accuracy for HD patients presenting with chest pain or dyspnea is uncertain.
Furthermore, because a substantial proportion of HD patients have elevated cardiac troponins in the absence of acute coronary syndrome, a key clinical challenge is to differentiate a clinically relevant rise in cardiac troponin level from its background elevation. We therefore investigated (1) whether the severity of renal disease is associated with increased baseline high-sensitivity troponin T levels and (2) the diagnostic accuracy of high-sensitivity cardiac troponin T (hs-cTnT) levels measured in patients presenting with acute chest pain or dyspnea at enrollment, and the dynamic change in these levels after 3 hours for AMI in HD patients.
MATERIALS AND METHODS

Study Population
In the West China Hospital of Sichuan University (Chengdu, China), for the period between September 2009 and December 2013, we enrolled HD patients from the nephrology department who on routine predialysis therapy showed signs of chest pain or dyspnea. In addition, on the basis of clinical symptoms, clinicians found these patients to have possible acute coronary syndrome and decided to order troponin T tests. Exclusion criteria were major surgery or trauma within the previous 4 weeks, pregnancy, intravenous drug abuse, age younger than 18 years or older than 85 years, and anemia (hemoglobin level , 10 g/dL). Signed informed consents were obtained from all participants or their guardians, and the study was approved by the Ethics Committee of West China Hospital, Sichuan University.
Clinical and Laboratory Data Collection
At the time of enrollment, a detailed clinical history was recorded, including age, sex, primary renal diagnosis, blood pressure, smoking history, coronary artery disease history, comorbidity (diabetes mellitus, heart failure, respiratory disease, hypertension, dyslipidemia, or renal anemia), and time undergoing hemodialysis.
Conventional cTnT was measured at enrollment and, if needed, the measurement was repeated after 6 to 9 hours with 99th percentiles of 0.01 ng/mL. The decision to order troponin T tests was at the discretion of the physician in charge. High-sensitivity cTnT was measured at enrollment and 3 hours after enrollment with 99th percentiles of 14 ng/L. All assays were performed on the Cobas-E601 analyzer using the electrochemiluminescence immunoassay (Roche Diagnostics, Penzberg, Germany): cTnT with a limit of detection of 0.01 ng/mL, a 99th percentile cutoff point of 0.01 ng/mL, and a coefficient of variation of 10% at 0.03 ng/mL; and hs-cTnT with a limit of detection of 0.003 ng/mL (3 ng/L), a 99th percentile cutoff point of 0.014 ng/mL (14 ng/L), and a coefficient of variation of 10% at 0.013 ng/mL (13 ng/L).
High-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, total cholesterol, serum calcium, serum phosphate, serum albumin, and serum creatinine concentrations were determined at enrollment via Modular-P800 (Roche Diagnostics). The estimated glomerular filtration rate (eGFR) calculated with the creatinine value was obtained by use of the simplified Modification of Diet in Renal Disease formula.
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Follow-up data were obtained 40 days after enrollment, and the primary end points were all-cause mortality.
Adjudication of the Final Diagnosis
Attending nephrology physicians were blinded to hs-cTnT results. The diagnosis of acute coronary syndrome was based on the patients' available clinical, laboratory, and imaging findings. If acute coronary syndrome was suspected, cardiologists were informed, who then usually hospitalized patients on their intermediate care ward for monitoring and treatment before potential coronary angiography.
The final diagnosis was adjudicated by both the nephrology physician and the cardiologist from the time of enrollment to the end of the 40-day follow-up period. A third cardiologist refereed in situations of disagreement. Acute myocardial infarction was adjudicated according to current guidelines. 16 Diagnosis of AMI, either non-ST segment elevation or ST elevation myocardial infarction, required a conventional cTnT above the 99th percentile value, associated with more than one of the following: symptoms of ischemia, new ST-T changes or a new Q wave on the electrocardiogram, and imaging showing new loss of viable myocardium.
Data Analysis
Continuous variables are presented as means (6SD) or medians (with the interquartile range), and categorical variables as numbers and percentages. For group comparisons, we used Student t test for normally distributed variables and nonparametric Mann-Whitney tests for nonnormally distributed variables. Categorical variables were compared with a v 2 test. The Kruskal-Wallis test was used for multiple comparisons. Correlation between hs-cTnT and renal function was quantified by the Pearson correlation coefficient. Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic accuracy of hs-cTnT measured in HD patients presenting with acute chest pain or dyspnea at enrollment, and its dynamic change after 3 hours, for AMI. The areas under the curve (AUCs) of hs-cTnT measured at enrollment and its dynamic change after 3 hours were compared by using the Mann-Whitney U Test. The best cutoff values were determined by the point farthest from the bisector of the ROC curve, plotted by SigmaPlot 10.0 (Systat Software Inc, San Jose, California). To determine the prognostic value of the hs-cTnT assays, we calculated Kaplan-Meier curves, using the logrank test for comparisons and Cox regression. Two-sided statistical tests were used for all analyses, and differences between groups were considered to be significant at P , .05. SPSS for Windows (version 13.0, Chicago, Illinois) was used to perform analyses.
RESULTS
Patient Characteristics
This study included 670 predialysis patients with chronic kidney disease who presented with chest pain or dyspnea and of whom 372 (55.5% of the group) were male; the mean age at enrollment was 56.7 years (Table 1) . A total of 80 patients (12% of the cohort) received a diagnosis of AMI. The primary renal diagnoses were diabetic nephropathy (n ¼ 125), obstructive uropathy (n ¼ 120), primary glomerulonephritis (n ¼ 229), hypertensive nephropathy (n ¼ 98), autosomal dominant polycystic kidney disease (n ¼ 52), chronic pyelonephritis (n ¼ 18), and unknown (n ¼ 28). Age; diastolic blood pressure; diabetes; prior coronary artery disease; time undergoing dialysis; high-density lipoprotein cholesterol, serum phosphate, hs-cTnT, and serum creatinine levels; and low eGFR value were positively associated with AMI. For the other characteristics we analyzed, there was no difference between the AMI and non-AMI groups (Table 2) .
Diagnostic Accuracy of hs-cTnT at Enrollment
Patients whose final diagnosis was not AMI (n ¼ 590) had high levels of hs-cTnT at enrollment (69.2 [36.9, 121.9] ng/L) including 572 patients (97%) with a plasma hs-cTnT concentration above the 99th percentile ( Figure 1) ; patients whose final diagnosis was AMI had higher (P , .001) levels of hs-cTnT at enrollment (118. 8 [65.7, 216 .0] ng/L; Figure 2 , A), which were 8.5 (4.7, 15.4) multiples of the 99th percentile for hs-cTnT levels (Figure 2, B) .
The AUC of hs-cTnT level for diagnosis of AMI was 0.68 (95% confidence interval [CI], 0.62-0.74; P , .001; Figure 3 ). The ROC-determined optimal cutoff value (107.7 ng/L) to separate AMI from non-AMI was greater than 7 times the 99th percentile value for hs-cTnT, with a sensitivity of 58%, specificity of 71%, positive predictive value of 21%, and negative predictive value of 93%.
Overall, hs-cTnT assays showed higher sensitivity at the 99th percentile than the best cutoff value (100% versus 58%; P , .001). The increase in sensitivity at the 99th percentile was associated with low specificity (3%) and positive predictive value (12%).
Dynamic Changes in hs-cTnT Concentration in AMI Diagnosis
Three hours after enrollment, the patients in the AMI group had higher (P , .001) relative and absolute change in The diagnostic accuracies of various cutoff values for relative and absolute change in hs-cTnT are provided in Table 3 . According to our ROC analyses (Figure 3) , the optimal diagnostic cutoffs for relative and absolute change in hs-cTnT were 24% and 32.6 ng/L, respectively. The relative and absolute change in hs-cTnT levels yielded better diagnostic accuracy for AMI, quantified by AUC, than did hs-cTnT determination at enrollment (0. Abbreviations: CAD, coronary artery disease; DBP, diastolic blood pressure; eGRF, estimated glomerular filtration rate; HDL, high-density lipoprotein; Hs-cTnT, high-sensitivity cardiac troponin T; LDL, low-density lipoprotein; SBP, systolic blood pressure. a Qualitative data are presented as No. (%). Quantitative data of normal distribution are presented as mean 6 SD (standard deviation). Quantitative data of nonnormal distribution are presented as median (25th and 75th percentiles). All data were collected within 24 hours after admission. Figure 1 . Distribution of high-sensitivity cardiac troponin T (hs-cTnT) levels at enrollment. The hs-cTnT levels were measured in hemodialysis participants with (n ¼ 80) and without (n ¼ 590) acute myocardial infarction (AMI).
was no difference in diagnostic accuracy between relative and absolute change in hs-cTnT levels 3 hours after enrollment (AUC: [95% CI, 0.82-0.96; P , .001] versus 0.88 [95% CI, 0.82-0.94; P , .001], P ¼ .80) ( Table 4) .
Prognostic Value of hs-cTnT Assays
At the end of the 40-day follow-up, of patients with a final diagnosis other than AMI (n ¼ 590), 33 (5.6%) had died-9 owing to infection; 8, heart respiratory circulatory failure; 4, ischemic stroke; the remaining patients withdrew from dialysis owing to general debility. None of the patients whose hs-cTnT concentration was less than 14 ng/L at enrollment had died. The risk of death was greater in patients with elevated hs-cTnT (P ¼ .02), and the degree of risk was dependent on the magnitude of elevation of hscTnT ( Figure 4) .
We examined the independent determinants of all-cause mortality within 40 days among patients whose final diagnosis was other than AMI, using multivariable logistic regression analyses of age, sex, and comorbidities such as hypertension, diabetes, smoking history, history of coronary artery disease, time undergoing dialysis, and hs-cTnT levels at enrollment. The results showed that age, diabetes, hscTnT levels, history of coronary artery disease, and time undergoing dialysis (hazard ratio: 1.5 (1.0, 1.8), 2.1 (1.2, 3.7), 1.3 (1.0, 1.5), 3.5 (2.0, 4.5), 2.5 (1.0, 4.5); P , .001) were significant independent predictors of death.
COMMENT This prospective study involving consecutive patients examined the diagnostic performance of an hs-cTnT assay for predialysis patients with acute chest pain or dyspnea at presentation, as well as dynamic change in hs-cTnT levels 3 hours after presentation, in early diagnosis of AMI. Our results indicate that (1) hs-cTnT concentrations are significantly correlated with renal function parameters such as Figure 3 . The area under the receiver-operating characteristic curves of high-sensitivity cardiac troponin T (hs-cTnT) levels, and dynamic changes in these levels, for the diagnosis of acute myocardial infarction (AMI). . Prognostic impact of elevation in high-sensitivity cardiac troponin T (hs-cTnT) in patients with final diagnosis other than acute myocardial infarction (AMI). Kaplan-Meier curves showing mortality within 40 days for patients whose final diagnosis was other than AMI (n ¼ 590), comparing patients with levels of ''sensitive'' troponins above the optimal cutoff value (as determined by receiver operating characteristic [ROC] curves), above the 99th percentile but below the optimal cutoff value, and below the 99th percentile.
eGFR and creatinine, and (2) the dynamic change in hscTnT levels 3 hours after presentation can be used to diagnose AMI in patients receiving chronic HD.
By using the 99th percentile of a healthy reference population to define an elevated troponin level, 30% to 85% of asymptomatic HD patients have been reported to have elevated troponin T levels. 17 In our study, using a newer-generation high-sensitivity troponin T assay, the percentage of HD patients with a diagnosis other than AMI who had a baseline level of hs-cTnT above the 99th percentile was 97%. This suggests that increasing the sensitivity of the assay may further increase the prevalence of detected cardiac troponin elevation in the HD population.
Clinically, the high incidence of elevated hs-cTnT levels in HD patients challenges the application of the 99th percentile (14 ng/L) as the threshold for AMI diagnosis. Our study showed that the specificity and positive predictive value were only 3% and 12.2%, respectively, when choosing 14 ng/L as the decision limit of hs-cTnT assays to diagnose AMI in HD patients. This finding illustrates the difficulty of using hs-cTnT levels to diagnose AMI in HD patients who present with chest pain or dyspnea.
In our study, we raised the threshold of serum hs-cTnT concentration to 107.7 ng/L, the best cutoff value as determined by ROC for diagnosis of AMI in HD patients. However, the diagnostic accuracy was still rather low (AUC: 0.68), with a sensitivity of 58% and a specificity of 71%. A similar result was reported in another study, 18 although patients in this study had renal insufficiency.
Wang and Wai-Kei 19 have recommended that a relative change in cardiac troponin levels of 20% or more, with at least 1 value above the 99th percentile, should be used to define AMI in patients undergoing dialysis who present with symptoms suggestive of acute coronary syndrome. Our study was the first to verify this idea, showing that using the relative and absolute change in hs-cTnT levels 3 hours after presentation significantly increases the diagnostic accuracy for AMI in HD patients presenting with chest pain or dyspnea, and it may aid in differentiating AMI from unrelated chest pain or dyspnea.
Our study demonstrated that an elevated hs-cTnT level in patients undergoing dialysis with a final diagnosis other than AMI was an independent risk factor for mortality within 40 days, reaffirming the prognostic value of hs-cTnT in patients undergoing dialysis. Our findings extend the results of previous studies 20, 21 investigating the short-term mortality of HD subjects with elevated levels of hs-cTnT.
Some studies [22] [23] [24] have indicated that HD can influence troponin levels, and one limitation of our study was that we only performed analyses on patients in predialysis. In addition, although chest pain is considered to be the cardinal manifestation of coronary ischemia, patients with both predialysis chronic kidney disease 25 and ESRD 26 present with chest pain as their chief concern much less frequently than do patients with normal renal function. In fact, fewer than 50% of patients undergoing dialysis who have AMI present with chest pain. In our study we only evaluated the diagnostic accuracy of hs-cTnT in patients with symptoms. Further studies are needed to establish an 
